MedTrace Logo

Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT06876402 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 367

Last updated 2025-05-23

No results posted yet for this study

Summary

GEMA-proN is an observational, multicenter, single cohort, retrospective clinical trial. The aim of the trial is to assess the prevalence, and prognostic value of genetic molecular alterations and investigate correlations with clinicopathological features in unselected patients with histologically confirmed non-small cell lung cancer (NSCLC).

Conditions

  • NSCLC (Non-small Cell Lung Cancer)

Sponsors & Collaborators

  • Hellenic Cooperative Oncology Group

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-09
Primary Completion
2024-10-13
Completion
2025-05-15

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06876402 on ClinicalTrials.gov